Health Care/Hospital
TransThera Announces the Global Multicenter Phase 3 Clinical Trial Completed First Patient Dosing in the US Evaluating Tinengotinib in FGFRi Relapsed/Refractory Patients with Cholangiocarcinoma
NANJING, China and GAITHURSBURG, Md., Dec. 21, 2023 /PRNewswire/ -- TransThera, a clinical-stage biopharmaceutical company dedicated to innovating differentiated drugs globally, today announces the first patient has been dosed in the US for the Phase 3 trial FIRST-308 of tinengotinib (TT-00420), ...
2023-12-21 21:45
1254
International Clinical Trial Results Released! Responding to the Virus Resurgence, Lianhua Qingwen Capsules Provide New Evidence
SINGAPORE, Dec. 21, 2023 /PRNewswire/ -- Recently, according to multiple reports from local Singaporean media, confirmed cases of COVID-19 are steadily increasing, with the average number of daily hospitalizations on the rise. The virus, once vigorously fought against, seems to be making a comeba...
2023-12-21 18:06
2085
CStone sells to Servier its exclusive rights to TIBSOVO® in Greater China and Singapore
* The deal enables CStone to prioritize its resources to focus on the development of first-in-class and best-in-class therapies with global rights. * The deal enables Servier to potentially bring additional indications and accessibility of TIBSOVO® to patients in Greater China (including main...
2023-12-21 17:10
1831
Everest Medicines' Partner Calliditas Therapeutics Announces Nefecon® the Only FDA-approved Treatment for IgA Nephropathy to Significantly Slow Kidney Function Decline
SHANGHAI, Dec. 21, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company")'s licensing partner Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") announced that the U.S. Food and Drug Administration (FDA) had approved Nefecon® delayed rele...
2023-12-21 10:30
6577
EVERISE ANNOUNCES SUCCESSFUL CLOSURE OF INVESTMENT BY WARBURG PINCUS, JOINING BROOKFIELD FOR THE NEXT PHASE OF GROWTH
NEW YORK, SINGAPORE and MUMBAI, Dec. 21, 2023 /PRNewswire/ -- Everise, a leading global healthcare services outsourcing company, announced today the successful completion of the company's previously announced investment from Warburg Pincus. Warburg Pincus joins existing investorBrookfield, valuin...
2023-12-21 10:16
4419
ENA Building Momentum Globally in Support of Emergency Nurses
Partnerships help gold standard TNCC and ENPC courses reach more international ED nurses SCHAUMBURG, Ill., Dec. 21, 2023 /PRNewswire/ -- After a year dedicated to expanding its international connections, theEmergency Nurses Association stands poised to reach more emergency nurses globally with k...
2023-12-21 09:00
1590
BioCity announces the first patient dosed with its anti-TIM-3 mAb BC3402 in Combination with IMFINZI for the Treatment of Advanced Hepatocellular Carcinoma in a Phase Ib/II Trial
WUXI, China, Dec. 20, 2023 /PRNewswire/ -- BioCity Biopharma today announced dosing of the first patient in a Phase Ib/II clinical trial of its anti-TIM-3 monoclonal antibody (mAb) BC3402 in combination with IMFINZI (durvalumab) for the treatment of advanced hepatocellular carcinoma (HCC) inCh...
2023-12-21 08:26
1371
YS Biopharma Responds to Unauthorized Press Release Regarding Extraordinary General Meeting
GAITHERSBURG, Md., Dec. 20, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious disea...
2023-12-21 05:30
1481
/DISREGARD RELEASE: YS Biopharma/
We are advised by YS Biopharma Co., Ltd. (NASDAQ:YS) that journalists and other readers should disregard the news release, "YS Biopharma Co., Ltd. to Hold Extraordinary General Meeting onDecember 28, 2023", issued on December 20, 2023 by YS Biopharma over PR Newswire, as the release contained err...
2023-12-21 05:15
2242
CellOrigin announced treatment of the first patient with CAR-M in China and reported the second generation of CAR-M for solid tumors
HANGZHOU, China, Dec. 20, 2023 /PRNewswire/ -- Recently, a CAR-macrophage therapy product (CAR-M) SY001 from CellOrigin Biotechnology (Hangzhou) Co., Ltd. was dosed to the first patient in a hospital inChina. "A single center, single-arm, dose-escalation, exploratory clinical trial to examine t...
2023-12-21 01:00
1501
EpiVax Licenses ISPRI Toolkit to Eisai for Preclinical in silico Immunogenicity Screening
PROVIDENCE, R.I., Dec. 21, 2023 /PRNewswire/ -- EpiVax, Inc. ("EpiVax"), an internationally recognized leader in the field of immunogenicity, today announced that Eisai Co. Ltd. ("Eisai") has licensed EpiVax's ISPRI toolkit for preclinical immunogenicity risk assessment of Eisai's robust biologic...
2023-12-20 23:45
1541
Genevoyager Unveils Gene Therapy CDMO Facility in Milestone Move
PHILADELPHIA, Dec. 20, 2023 /PRNewswire/ -- Genevoyager (Wuhan) Co., Ltd. (Genevoyager), a leading provider of one-stop CRO/CDMO services for gene therapy products, proudly announces the official opening of its Contract Development and Manufacturing Organization (CDMO) facility. This significant ...
2023-12-20 23:10
1341
Dx&Vx co-develops a bio-healthcare big data platform with LG CNS
- Possessing human genome and microbiome data in all clinical stages - Becoming a global bio-healthcare big data platform company SEOUL, South Korea, Dec. 20, 2023 /PRNewswire/ -- Dx&Vx will develop a bio-healthcare big data platform utilizing AI technology provided by LG CNS. Dx&Vx recently anno...
2023-12-20 22:00
1868
HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals to Showcase Ongoing Parkinson's Disease Program at the 7th Annual Sachs Associates Neuroscience Innovation Forum
ROCKVILLE, Md., Dec. 20, 2023 /PRNewswire/ -- HanAll Biopharma (KRX: 009420.KS), Daewoong Pharmaceutical (KRX: 069620.KS), and NurrOn Pharmaceuticals announced their participation in the 7th Annual Sachs Associates Neuroscience Innovation Forum. The event is scheduled to take place onJanuary 7th...
2023-12-20 20:00
1230
Fapon Shines at JITMM 2023
DONGGUAN, China, Dec. 20, 2023 /PRNewswire/ -- Fapon, a global leading life sciences company, showcased its expertise at the Joint International Tropical Medicine Meeting (JITMM) 2023, the leading tropical-medicine conference in Southeast Asia held in Bangkok, Thailand, from December 12th to 15th....
2023-12-20 17:39
1901
INNOTIER TEAMED UP WITH TERESA MO & JENNIFER YU TO LAUNCH A NEW FASHIONABLE COLLECTION FOR EPIDEMIC PREVENTION
HONG KONG, Dec. 20, 2023 /PRNewswire/ -- This winter is the first winter in Hong Kong after the lifting of the mask mandate. The Department of Health expects a high chance of outbreaks of upper respiratory tract diseases, mainly seasonal influenza.Hong Kong has already experienced a summer flu ou...
2023-12-20 10:00
1719
International Collaboration to Improve Cancer Care in Sub-Saharan Africa Updates Resources for Sixth Year
Collective effort to optimize and standardize treatment practices now covers more than 90% of adult cancer incidences plus an increasing number of pediatric diseases. PLYMOUTH MEETING, Pa., Dec. 20, 2023 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading ac...
2023-12-20 09:06
1445
InxMed Enters License Agreement with Escugen to Develop Next-Generation ADCs
NANJING, China, Dec. 19, 2023 /PRNewswire/ -- InxMed, a clinical-stage biotechnology company dedicates on developing innovative therapies against drug resistance, and Escugen, a clinical-stage antibody–drug conjugate (ADC) company, today announced that InxMed licensed EZWi-Fit® linker-payload pl...
2023-12-20 09:00
1388
Lynk Pharmaceuticals Announced First Rheumatoid Arthritis Patient Dosed in Phase Ⅲ Clinical Study of LNK01001
BOSTON and HANGZHOU and SHANGHAI, China, Dec. 20, 2023 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced that it has dosed the first patient with Rheumatoid Arthritis (RA) in a Phase Ⅲ clinical trial...
2023-12-20 08:00
2078
ShiraTronics Announces Landmark Achievement: World's First Implant of its Innovative Chronic Migraine System
MINNEAPOLIS, Dec. 20, 2023 /PRNewswire/ -- ShiraTronics, Inc., a trailblazing clinical-stage medical device company, today announced a landmark achievement with the successful implantation of its Chronic Migraine System in the world's first six patients. This remarkable milestone represents a sig...
2023-12-19 23:12
1562
Week's Top Stories
Most Reposted
Earth Day 2024: Angel Yeast Continues to Tackle Plastic Pollution Challenges With Bio-based Material Solutions
[Picked up by 294 media titles]
2024-04-22 16:00
Trina Solar and PetroGreen Partner to Accelerate Philippine Solar Adoption with 117MW Supply Agreement
[Picked up by 291 media titles]
2024-04-22 06:00
Revenue Surpasses 50 Billion: BlueFocus Accelerates Towards the AI Native Era
[Picked up by 275 media titles]
2024-04-23 15:43
INTAMSYS Becomes 3D Printing Equipment Supplier for the WORLDSKILLS LYON 2024 COMPETITION
[Picked up by 273 media titles]
2024-04-24 17:09
Introducing Wacom Movink: The first OLED pen display, and the thinnest and lightest Wacom pen display ever
[Picked up by 268 media titles]
2024-04-24 13:00
Most Read
Automation Anywhere Appoints Tim McDonough as Chief Marketing Officer to Drive Global Awareness and Growth for the Leader in AI-Powered Automation
2024-04-24 03:57
5947
Earth Day 2024: Angel Yeast Continues to Tackle Plastic Pollution Challenges With Bio-based Material Solutions
2024-04-22 16:00
4447
Trina Solar and PetroGreen Partner to Accelerate Philippine Solar Adoption with 117MW Supply Agreement
2024-04-22 06:00
4041
TCTM Filed 2023 Annual Report on Form 20-F
2024-04-20 05:48
3322
Dingdong Files Its Annual Report on Form 20-F
2024-04-20 05:00
3067